These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 4456974

  • 1. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK, Jagenburg R, Rödjer S, Svanborg A.
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract] [Full Text] [Related]

  • 2. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.
    Andersson I, Granerus AK, Jagenburg R, Svanborg A.
    Acta Med Scand; 1975 Nov; 198(5):415-20. PubMed ID: 1199816
    [Abstract] [Full Text] [Related]

  • 3. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y, Yoshida M, Obayashi T, Ueki A.
    Rinsho Shinkeigaku; 1976 Jul 01; 16(7):511-9. PubMed ID: 986921
    [No Abstract] [Full Text] [Related]

  • 4. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
    Perret J, Feuerstein C, Pellat J, Serre F, Gavend M, Tanche M.
    Rev Neurol (Paris); 1977 Nov 01; 133(11):627-36. PubMed ID: 601391
    [Abstract] [Full Text] [Related]

  • 5. Intermittent levodopa therapy in parkinsonism.
    Koller WC.
    Adv Neurol; 1983 Nov 01; 37():45-50. PubMed ID: 6407286
    [Abstract] [Full Text] [Related]

  • 6. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T, Kuhn W.
    Mov Disord; 2009 Jul 15; 24(9):1339-43. PubMed ID: 19425084
    [Abstract] [Full Text] [Related]

  • 7. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
    Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G.
    Clin Chem; 2001 Jun 15; 47(6):1102-4. PubMed ID: 11375298
    [No Abstract] [Full Text] [Related]

  • 8. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E, Mogensen P, Jacobsen J, Pakkenberg H, Christensen NJ.
    Acta Neurol Scand; 1995 Aug 15; 92(2):116-21. PubMed ID: 7484057
    [Abstract] [Full Text] [Related]

  • 9. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
    Petelin LS, Vartanian KZ, Romenskaia LKh.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977 Aug 15; 77(12):1810-3. PubMed ID: 602554
    [Abstract] [Full Text] [Related]

  • 10. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.
    Amino Acids; 2005 Mar 15; 28(2):157-64. PubMed ID: 15750845
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W, Naoi M, Narabayashi H.
    J Neurol Sci; 1996 Jul 15; 139(1):141-8. PubMed ID: 8836986
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Interaction of L-DOPA and pyridoxine (a review of the literature)].
    Uspenskiĭ AE.
    Farmakol Toksikol; 1977 Jul 15; 40(6):722-33. PubMed ID: 340258
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS, Ericsson AD, McCann DS.
    Neurology; 1971 May 15; 21(5):540-9. PubMed ID: 5104098
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.